Abivax: reports FY 2023 and reiterates timelines
Abivax reported its FY 2023 financial results, which highlighted the total EUR 500m raised in 2023 (incl. EUR 130m capital increase, two structured debt financing transactions aggregating EUR 150m and EUR 223.3m US IPO). In particular, the financial results highlighted i) operating loss at EUR -127
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.